1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
郭慧娴, 周慧玲, 朱晓蔚, 等. 结直肠癌分子靶向治疗的研究进展. 癌症进展, 2022, 20(19): 1950-1953.
|
3. |
Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 2013, 369(11): 1023-1034.
|
4. |
岳育民, 陈曦, 王慧, 等. 结直肠癌肝转移切除术后患者RAS基因突变影响生存的整合分析. 中国普外基础与临床杂志, 2022, 29(12): 1583-1590.
|
5. |
Cercek A, Braghiroli MI, Chou JF, et al. Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations. Clin Cancer Res, 2017, 23(16): 4753-4760.
|
6. |
Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol, 2011, 6: 479-507.
|
7. |
Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol, 2016, 34(2): 179-185.
|
8. |
Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther, 2021, 6(1): 386. doi: 10.1038/s41392-021-00780-4.
|
9. |
Macerola E, Proietti A, Poma AM, et al. Molecular alterations in relation to histopathological characteristics in a large series of pediatric papillary thyroid carcinoma from a single institution. Cancers (Basel), 2021, 13(13): 3123. doi: 10.3390/cancers13133123.
|
10. |
Siraj AK, Bu R, Prabhakaran S, et al. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol Cancer, 2014, 13: 168. doi: 10.1186/1476-4598-13-168.
|
11. |
Riquelme E, Behrens C, Lin HY, et al. Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS Oncogene mutations. Cancer Research, 2016, 76(3): 675-685.
|
12. |
Cook JH, Melloni GEM, Gulhan DC, et al. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun 2021, 12(1): 1808. doi: 10.1038/ s41467-021-22125-z.
|
13. |
Imamura Y, Morikawa T, Liao X, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1 075 BRAF Wild-Type colorectal cancers. Clinical Cancer Research, 2012, 18(17): 4753-4763.
|
14. |
Modest DP, Ricard I, Heinemann V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO Colorectal Cancer Study Group. Ann Oncol 2016, 27(9): 1746-1753.
|
15. |
Yuan Y, Liu Y, Wu Y, et al. Clinical characteristics and prognostic value of the KRAS mutation in chinese colorectal cancer patients. Int J Biol Markers, 2021, 36(2): 33-39.
|
16. |
Koulouridi A, Karagianni M, Messaritakis I, et al. Prognostic value of KRAS mutations in colorectal cancer patients. Cancers (Basel), 2022, 14(14): 3320. doi: 10.3390/cancers14143320.
|
17. |
Guo TA, Wu YC, Tan C, et al. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1 834 Chinese patients with stageⅠ–Ⅳcolorectal cancer. Int J Cancer, 2019, 145(6): 1625-1634.
|
18. |
Bao X, Zhang H, Wu W, et al. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. J Immunother Cancer r, 2020, 8(2): e001437. doi: 10.1136/jitc-2020-001437.
|
19. |
Kim C G, Ahn J B, Jung M, et al. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer, 2016, 115(1): 25-33.
|
20. |
Provenzale D, Ness RM, Llor X, et al. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2. 2020. J Natl Compr Canc Netw, 2020, 18(10): 1312-1320.
|
21. |
Lai E, Pretta A, Impera V, et al. BRAF-mutant colorectal cancer, a Different Breed Evolving. Expert Rev Mol Diagn, 2018, 18(6): 499-512.
|
22. |
叶胜兵, 李锐, 王小桐, 等. 1 889例结直肠癌MSI、K-ras、N-ras和B-raf基因状态以及临床病理特征分析. 诊断病理学杂志, 2023, 30(1): 1-5.
|
23. |
Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res, 2011, 17(5): 1122-1130.
|
24. |
Roth A D, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stageⅡand Ⅲ resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol, 2010, 28(3): 466-474.
|
25. |
Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stageⅡ/Ⅲ colon cancer. J Natl Cancer Inst, 2012, 104(21): 1635-1646.
|
26. |
Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage Ⅲ colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res, 2009, 15(23): 7322-7329.
|
27. |
Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol, 2011, 29(10): 1261-1270.
|
28. |
Yoon HH, Tougeron D, Shi Q, et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stageⅢ colon cancers from an adjuvant chemotherapy trial (N0147 Alliance). Clin Cancer Res, 2014, 20(11): 3033-3043.
|
29. |
Lee DW, Kim KJ, Han SW, et al. KRAS mutation is associated with worse prognosis in stageⅢ or high-risk stageⅡ colon cancer patients treated with adjuvant folfox. Ann surgical Oncol, 2015, 22(1): 187-194.
|
30. |
马甘青, 张丹, 李路遥, 等. 转移性结直肠癌药物治疗研究进展. 中国普外基础与临床杂志, 2023, 30(7): 889-896.
|
31. |
Tian J, Chen JH, Chao SX, et al. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med, 2023, 29(2): 458-466.
|
32. |
Ciardiello D, Maiorano BA, Martinelli E. Targeting KRASG12C in colorectal cancer: The beginning of a new era. ESMO Open, 2023, 8(1): 100745. doi: 10.1016/j.esmoop.2022.100745.
|